Ovoca Bio (LSE:OVB) Change In Inventory : £0.02 Mil (TTM As of Jun. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Ovoca Bio Change In Inventory?

Ovoca Bio's change in inventory for the quarter that ended in Jun. 2024 was £0.00 Mil. It means Ovoca Bio's inventory stayed the same from Dec. 2023 to Jun. 2024 .

Ovoca Bio's change in inventory for the fiscal year that ended in Dec. 2023 was £0.04 Mil. It means Ovoca Bio's inventory declined by £0.04 Mil from Dec. 2022 to Dec. 2023 .

Ovoca Bio's Total Inventories for the quarter that ended in Jun. 2024 was £0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Ovoca Bio Change In Inventory Historical Data

The historical data trend for Ovoca Bio's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovoca Bio Change In Inventory Chart

Ovoca Bio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

-0.02

-0.06

0.15

0.04

Ovoca Bio Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Change In Inventory	Get a 7-Day Free Trial															-0.03	0.08	0.02	0.02	-

Ovoca Bio Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.02 Mil.

Ovoca Bio (LSE:OVB) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Ovoca Bio's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 2
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Ovoca Bio's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Ovoca Bio's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Ovoca Bio Change In Inventory Related Terms

Thank you for viewing the detailed overview of Ovoca Bio's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovoca Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovoca Bio PLC (LSE:OVB) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

OVXA:Ireland OVB.GB:UK OVXA:Germany

Address

17 Pembroke Street Upper, Dublin, IRL, D02 AT22

Website

https://www.ovocabio.com

Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.